RESEARCH ARTICLE

Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam

Lynn Peters1, Linus Olson2,3, Dung T. K. Khu3,4, Sofia Linnros1, Ngai K. Le3,5, Häkan Hanberger6, Ngoc T. B. Hoang5, Dien M. Tran7,8, Mattias Larsson2,3*

1 Global Health program, Karolinska Institutet, Stockholm, Sweden, 2 Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden, 3 Training and Research Academic Collaboration Sweden-Vietnam, Karolinska Institutet, Stockholm, Sweden, 4 Department of Neonatology, Vietnam National Children’s Hospital, Hanoi, Vietnam, 5 Department of Microbiology, Vietnam National Children’s Hospital, Hanoi, Vietnam, 6 Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden, 7 Research Institute for Child Health, Hanoi, Vietnam, 8 Department of Surgery, Vietnam National Children’s Hospital, Hanoi, Vietnam

* mattias.larsson@ki.se

Abstract

Background
Antibiotic resistance (ABR) is an increasing burden for global health. The prevalence of ABR in Southeast Asia is among the highest worldwide, especially in relation to hospital-acquired infections (HAI) in intensive care units (ICU). However, little is known about morbidity and mortality attributable to ABR in neonates.

Aim
This study aimed to assess mortality and the length of hospitalization attributable to ABR in gram-negative bacteria (GNB) causing HAI in a Vietnamese neonatal ICU (NICU).

Methods
We conducted a prospective cohort study (n = 296) in a NICU in Hanoi, Vietnam, from March 2016 to October 2017. Patients isolated with HAI caused by GNB were included. The exposure was resistance to multiple antibiotic classes, the two outcomes were mortality and length of hospital stay (LOS). Data were analysed using two regression models, controlling for confounders and effect modifiers such as co-morbidities, time at risk, severity of illness, sex, age, and birthweight.

Results
The overall case fatality rate was 44.3% and the 30 days mortality rate after infection was 31.8%. For every additional resistance to an antibiotic class, the odds of a fatal outcome
supported the study financially through the TRAC (Training and Research Academic Collaboration) Sweden-Vietnam. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Ethical considerations. The study was approved by the ethical board of the Vietnam Children’s Hospital in 2015. All caretakers were informed about the study procedure and gave their consent prior to enrollment in the study. Caretakers could withdraw their children at any time from the study without justification.

**Competing interests:** The authors have declared that no competing interests exist.

increased by 27% and LOS increased by 2.1 days. These results were statistically significant ($p < 0.05$).

**Conclusion**

ABR was identified as a significant risk factor for adverse outcomes in neonates with HAI. These findings are generally in line with previous research in children and adults. However, heterogeneous study designs, the neglect of important confounders and varying definitions of ABR impair the validity, reliability, and comparability of results.

**Introduction**

Antimicrobial resistance (AMR), in general, is the ability of a pathogen to withstand the effects of antimicrobials. Consequently, simple infections can become lethal again without effective tools to fight them. Antibiotic resistance (ABR) in bacteria is a consequence of selective antibiotic pressure in the environment, in human and veterinary medicine and food production or cross-transmission between individuals [1–4]. With a high number of antibiotics used in a limited area, healthcare settings and intensive care units (ICU) in particular are one of the main routes of emergence and transmission for resistant bacteria [3,5–10].

Hospital-acquired infections (HAI) are infections that occur during hospitalization and are often caused by gram-negative bacteria (GNB) [11,12]. As healthcare settings facilitate the spread of resistant bacteria, HAI are more likely to be caused by resistant bacteria than community-acquired infections. HAI with ABR bacteria are more difficult to treat and are associated with increased hospitalization time and mortality [9]. AMR is estimated to be responsible for 30,000 deaths per year in Europe [13] and 23,000 in the USA [2]. Emergence and spread of AMR are particularly high in low and middle-income countries (LMIC). Of all WHO regions, it is expected to be the highest in Southeast Asia [3], leading to 38,000 deaths per year in Thailand [3,14]. The emergence of multi- (MDR), extensive (XDR) and pan-drug resistant (PDR) bacteria (for definition see Magiorakos et al. [15]) is particularly worrying since clinicians are running out of treatment options and it has been estimated that AMR will cause 10 million deaths per year by 2050 if we fail to take appropriate actions now [16]. AMR and especially MDR are thus a significant burden for global health requiring immediate and coordinated action from the global community.

Neonates (babies in their first 28 days of life) and infants (first year of life) have a premature immune system and are a particularly vulnerable population for infectious diseases and hence resistant bacteria [8,11,17–19]. In LMIC, neonatal infection rates are 3 to 20 times higher than in high-income countries (HIC) and 40% of neonatal deaths are attributable to infectious diseases in general [11,20,21]. Focusing on HAI specifically, rates of HAI in neonatal intensive care units (NICU) are 9 times higher in LMIC than in HIC. They affect 20% to 50% of all NICU admissions and fatality rates range from 12% to 52% [8,11]. The most common types of HAI are pneumonia and bloodstream infections, mainly caused by GNB with increasing rates of ABR [8,11,18,22–26].

So far, little is known about mortality and morbidity attributable to ABR infections in neonates and young infants. The length of hospital stay (LOS) can serve as a measurement of morbidity and is also associated with higher costs [27–29]. Previous research indicates an increased mortality and LOS as a measurement of morbidity in neonates and infants due to ABR [24,25,29–36]. However, most studies focus on a single pathogen, type of infection or
antibiotic class. Only a few studies appropriately adjust for confounders and effect modifiers, which might bias results.

The aim of this study was to assess if multiple antibiotic resistance (MAR) is a risk factor for mortality and prolonged LOS in patients from a NICU in Hanoi, Vietnam with HAI caused by GNB.

2. Materials and methods

Methods

Setting, data collection and inclusion criteria. A total of 327 neonates and young infants from the NICU of the Vietnam National Children’s Hospital in Hanoi were included from March 2016 to October 2017 (18 months). Data were collected from patient records. Patients were considered eligible for the study if they met the following inclusion criteria: HAI (pneumonia, bloodstream infections, surgical site infections or urinary tract infections) diagnosed by the attending physician familiar with the clinical and laboratory parameters according to the ECDC criteria [37] (e.g. fever, tachycardia, metabolic acidosis, elevated CRP levels, infiltrate in case of pneumonia) caused by antibiotic-resistant bacteria and treated in isolation care. Patients that died within 24 hours after admission were excluded, as well as those cases with culture-negative HAI. Before cases were subsequently included in our cohort, the diagnosis ‘HAI’ was verified by an experienced researcher also acquainted with the ECDC criteria. Demographic data were collected from all included patients. Further analysis focused on patients with an HAI caused by Klebsiella pneumonia, Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli and/ or Serratia marcescens (n = 296) to exclude possible intrinsic resistances in gram-positive as well as in fungal species.

Study design and variables. The study was designed as a prospective cohort study with all-cause mortality and the LOS as the outcomes assessed in two models. The two endpoints were either ‘death’ or ‘discharged healthy’. In this setting, patients with a fatal diagnosis are frequently withdrawn from treatment, with death at home as the most common outcome. Those patients were added to the crude mortality rate with ‘death’ as outcome, the date of discharge was defined as endpoint due to loss of follow up after discharge.

The exposure of interest was the antibiotic resistance pattern of the bacteria causing the HAI. The definition of this variable differs across earlier studies. In order to provide comparability within the field, a group of international experts published definitions of MDR, XDR, and PDR for different bacterial species, based on the number of antibiotic classes a species is resistant to. Resistance was defined as non-susceptibility to at least one agent of an antibiotic class [15]. The data collected was based on the local ABR testing practice for GNB and hence did not cover all classes required to meet the definition. Therefore, it was not possible to code the exposure as a binary variable according to this classification for MDR, XDR, and PDR. To ensure some comparability nonetheless, we summed the number of antibiotic classes a species was resistant to, as did Magiorakos et al. However, we used the continuous variable for the analysis without dichotomization. The different classes (and respective agents) were: antipseudomonal cephalosporins (ceftazidime, cefepime), antipseudomonal penicillins (piperacillin/tazobactam, ticarcillin), antipseudomonal carbapenems (imipenem, meropenem), antipseudomonal fluoroquinolones (ciprofloxacin, levofloxacin), aminoglycosides (amikacin, gentamicin, tobramycin), monobactams (aztreonam), polymyxins (colistin), folate pathway inhibitors (trimethoprim/sulfamethoxazole).

Based on previous literature [27,38–41], we added different confounders and effect modifiers as co-variates to our model:
We included the effect modifiers ‘age at admission’ and sex. Gestational age (pre-term vs. full-term) was strongly correlated with birthweight, causing multicollinearity. Therefore, we picked birthweight as a continuous variable to adjust for prematurity in our model. We included the ‘time at risk’ as a confounder, referring to the time from admission until a positive culture was obtained marking the onset of the HAI. The emergence of ABR is time-dependent and exposure to healthcare bears the risk of acquiring a resistant strain—the longer the stay, the higher the risk [40]. Consequently, a prolonged LOS can cause ABR. However, we aimed to assess LOS as a consequence of ABR and hence needed to control for the time at risk before the onset of HAI.

Secondly, we included the number of common co-morbidities to adjust for underlying diseases, namely: respiratory distress syndrome, persistent ductus arteriosus, pulmonary hypertension, hyperbilirubinemia, congenital heart disease, intraventricular hemorrhage, epilepsy, megacolon, bronchopulmonary dysplasia, necrotizing enterocolitis, hydrocephalus, and down syndrome.

Furthermore, the severity of illness must be considered. For adults, validated and updated scores including clinical and laboratory information are often applied. In neonates, several scores exist (CRIB: clinical risk index for babies; SNAP-PE: score for neonatal acute physiology [perinatal extension]; NMPI: neonatal mortality prognosis index; NTISS: neonatal therapeutic intervention scoring system; NBRS: neurological risk score), however, every score has considerable disadvantages [42,43]: Most scores were designed in the last century and are therefore not adjusted to the medical progress made in neonatal care. Furthermore, most existing scores were designed to predict mortality in premature neonates with a range of problems, not specifically to assess the severity of an infection. This explains why certain scores (CRIB, SNAP, NMPI, SINKIN) are only validated for the first 12 or 24 hours of life, others only for neonates with very low birthweight (CRIB, CRIB II, Berlin score) and are therefore not applicable to our cohort with neonates and young infants, both premature and mature. Others (SNAP, SNAP-PE, NTISS) require a vast number of parameters which is not feasible in our setting. To control for ‘severity of illness’ nevertheless, we collected those parameters available and recommended in most scoring systems, namely birthweight, gestational age, gender and malformations, here labelled ‘co-morbidities’. As mentioned earlier, these factors were entered as confounders in the regression model, except gestational age which was later excluded because of multicollinearity. Most scores furthermore mention respiratory failure (CRIB, SNAP, SNAP-II, Berlin score, NMPI, SINKIN, NBRS, NTISS) as an important determinant of the severity of illness, others low urine output (SNAP-II, SNAPPE-II, NTISS), seizures (NBRS, SNAP, SNAP-II, NTISS) or metabolic acidosis (CRIB, CRIB II, Berlin score, NBRS, SNAP, SNAP-II, NTISS). Most of these conditions require invasive procedures such as endotracheal intubation, a urinary tract catheter or a venous catheter to administer treatment. Therefore, the sum of invasive devices (endotracheal tubes, urinary tract catheters, central and peripheral venous catheters) needed during the entire stay served as a surrogate parameter, similar as in the NTISS, and was entered as a confounder in the regression model. In ideal circumstances, an updated, reliable and validated score applicable to our cohort including feasible parameters would present the most preferable approach to adjust for ‘severity of illness’. However, including those factors widely used in existing disease severity scores for neonates (birthweight, gestational age, gender, co-morbidities) and the number of invasive devices as a proxy seems the most feasible approach to control for ‘severity of illness’ given the limitations of existing scoring systems and our setting.

Crude mortality was added as a co-variate to the model assessing LOS to avoid bias due to the phenomenon known as ‘competing risks’. In short, neonates dying during in-hospital
treatment have a shorter LOS than those that survive. Assuming that ABR is associated with mortality, it would wrongly be linked to a shorter LOS if not adjusted for.

Some research indicates that polymicrobial infections (infections caused by multiple pathogens) are associated with ABR and mortality [44]. We intended to control for this possible confounder, however, it was strongly correlated with the exposure MAR and hence excluded because of multicollinearity.

**Laboratory procedures.** Laboratory information regarding culture type (tracheal aspirate or nasopharynx culture in pneumonia, blood culture in bloodstream infections, urine culture in urinary tract infections, wound culture in surgical site infections), culture date and result (isolated pathogen and resistance testing) was obtained from patients’ records. The procedures respected the guidelines of the Clinical and Laboratory Standards Institute. Antibiotic resistance was tested using the VITEK2 system (bioMérieux) and confirmed by broth microdilution, since the VITEK2 system is not reliable for all substances, e.g. colistin. Intermediate resistance was considered resistant.

**Statistical analysis.** Statistical analysis was performed using IBM SPSS version 21. Demographic characteristics, type of HAI, pathogens isolated and their ABR patterns were described with mean, median and standard deviation. The case fatality rate and the 30 days mortality rate from admission and infection were calculated. Descriptive statistics are based on the original data set. Prior to conducting multivariable analyses, missing data were handled using multiple imputation. Variables were tested for normal distribution, heavily skewed variables were log transformed to approach normality prior to the multiple imputation process and re-transformed afterwards. Multiple imputation was performed before categorizing variables to prevent loss of information. Since multiple imputation might weaken the influence of effect modifiers on the outcome, the dataset was split according to the dichotomous variable ‘gestational age’ (pre-term vs. full-term), which was assumed to be the strongest effect modifier in this study [45] and merged again after the multiple imputation process. The number of data-sets generated was determined using the formula suggested by Newgard and Haukoos [46], aiming for a relative efficiency of at least 95%, which is considered a high rate. A table giving an overview of the proportion of missing data in each variable is provided in the supporting information (S1 Table).

Afterwards, two regression models were created: a logistic regression model with mortality as a binary outcome and a linear regression model with LOS as a linear outcome, both with MAR as exposure. The models were adjusted for the co-variates discussed earlier. All variables were entered simultaneously. With a sample size of n = 296 and up to eight co-variates entered in the models, the power level was sufficient to detect even small effect sizes (power level set at 80%) [47–49]. Results were considered significant with a p-value smaller than 0.05.

Table 1 summarizes the research problems as well as the conceptual framework and the statistical analyses used to address them.

Since linear regression is sensitive to outliers, those outliers exceeding three standard deviations were identified (two cases in the original dataset and between no case and four cases in the imputed sets). The Cook’s distance, however, did not show a value larger than one in any of those cases (maximum of 0.054 in original data set and 0.092 in imputed data sets), therefore the cases were kept in the analysis.

**Ethical considerations.** The study was strictly observational, no interventions were performed, data was collected from patients’ records only without influencing further treatment. Identities of the children where not included in the data but a unique identifier for each patient. Therefore, the caretaker’s consent was not required according to the ethical board of the Vietnam Children’s Hospital when ethical approval was given in 2015.
3. Results

Descriptive statistics

**Demographic characteristics.** Out of 327 participants, 62.4% were male and 37.6% female. Almost two thirds were born pre-term (64.2%). The main mode of delivery was vaginal (60.9%), followed by a planned cesarean section (27.2%) and a smaller number of emergency cesarean sections (5.8%). Table 2 displays further demographical characteristics of the study population.

**Hospital-acquired infection and causative pathogens.** The predominant HAI were pneumonia (81.3%) and sepsis (49.2%). Sepsis referred to infections with positive blood cultures and included both primary bloodstream infections and secondary sepsis resulting from pneumonia. Other HAI were meningitis, gastroenteritis (0.9% each), surgical site infections and urinary tract infections (0.3% each). The pathogens mainly isolated from the infection site were *Acinetobacter baumanii* (27.9% of all isolates), *Klebsiella pneumoniae* (25.3%), *Pseudomonas aeruginosa* (20.5%), *Escherichia coli* (9.0%), *Serratia marcescens* (2.7%), *Staphylococcus aureus* (MRSA, 1.9%).

In total, 58.4% of HAI were caused by one pathogen, 27.5% were caused by two and 14.1% by three or more pathogens.

| Table 1. Overview of methodological approach. |
|---------------------------------------------|
| **1. Descriptive statistics in neonates with hospital-acquired infections (HAI) (n = 327)** |
| Description of study population | Demographic characteristics, type of hospital-acquired infections, pathogens isolated, antibiotic resistance patterns |
| Description of outcomes | Case fatality rate, 30 days mortality rate, length of hospital stay |
| **2. Risk factors for adverse outcomes in neonates with HAI caused by gram-negative bacteria (n = 296)** |
| Outcome | Mortality |
| Exposure | Length of hospital stay (LOS) |
| Regression model | Logistic regression |
| Co-variates (confounders and effect modifiers) | Time at risk |
| Multiple antibiotic resistance (MAR) (number of resistances to different antibiotic classes) | Number of co-morbidities |
| | Number of invasive devices |
| | Sex |
| | Age at admission |
| | Birthweight |
| Excluded co-variates (because of multicollinearity) | Gestational age |
| | Polymicrobial infection |

https://doi.org/10.1371/journal.pone.0215666.t001

| Table 2. Demographical information. |
|-------------------------------------|
| n | Mean | Standard-deviation | Median | Minimum | Maximum |
|-----------------|----------|------------------|---------|---------|---------|
| Birthweight in gram | 315 | 1984.3 | 891 | 1800 | 4500 |
| Gestational age at birth in weeks | 363 | 34.0 | 5.2 | 34 | 40 |
| Age at admission in days | 326 | 8.0 | 9.2 | 4 | 44 |
| Weight at admission in gram | 318 | 2011.2 | 924.8 | 1815 | 4800 |

Total n = 327, included number of participants due to missing data given respectively

https://doi.org/10.1371/journal.pone.0215666.t002
Since the study focuses on GNB, further calculations were based on HAI caused by *Acinetobacter baumanii*, *Klebsiella pneumonia*, *Pseudomonas aeruginosa*, *Escherichia coli* or *Serratia marcescens* as at least one of the isolates (n = 296, 90.5% of all cases). The proportion of ABR in the isolates ranged from 10% (colistin resistance) to over 97% (cephalosporin resistance). Table 3 shows the proportion of ABR to different antibiotic classes displayed by the main isolates.

This study focuses on the effect of MAR on treatment outcome. Fig 1 displays MAR, i.e. the number of different antibiotic classes isolated GNB were resistant to. Most patients (64%) had HAI caused by GNB with ABR to between five and seven antibiotic classes.

Descriptive statistics of outcomes. Mean total LOS in the initial study population (n = 327) was 38.7 days (SD 26.0 days) with a median of 30 days. Of all patients, 46.2% were discharged in good health while 44.3% died or were withdrawn with a fatal diagnosis (case fatality rate). Of those that died, 57.0% died within 30 days after admission and 71.7% within 30 days after infection. For the initial study population (n = 327), the 30 days mortality rate after admission was hence 25.3% and after infection 31.8%. Table 3 summarizes the outcomes in relation to the HAI and the GNB isolated.

Multivariable analysis

All-cause mortality. A logistic regression model assessed the effect of MAR in GNB causing HAI in neonates on the likelihood to die while adjusting for possible confounders. The model $\chi^2$ (df = 7) = 21.877, $p = 0.003$, Nagelkerke’s $R^2 = 11.8\%$ classified 62.7% of cases correctly. With every increase in the score of MAR, i.e. for every additional resistance to an
antibiotic class, the odds of a fatal outcome increased by 27% (c.f. Table 4). This result was statistically significant ($p = 0.007$).

**Length of hospital stay.** To assess the effects of MAR on LOS, a multiple linear regression was conducted. A significant model $F = 19.884$ (df = 8; $p < 0.001$, standard error = 21.272) explained 41.6% ($R^2$) of the outcome’s variance, which is a moderate proportion. The regression coefficients are listed in Table 5.

Entered in the regression equation, LOS significantly increased by 2.1 days for every additional resistance to an antibiotic class. Furthermore, a lower birthweight was associated with an increased LOS, however with a smaller effect size compared to the MAR score. Mortality was almost significantly ($p = 0.052$) correlated with LOS. The two significant variables account for 11.6% (birthweight) and 2.0% (MAR score) of the outcome’s variance and therefore influence LOS to a larger extent than other independent variables.

**Discussion**

In a prospective cohort study, we assessed the effect of multiple antibiotic resistance (MAR) in gram-negative bacteria (GNB) causing hospital-acquired infections (HAI) in Vietnamese neonates and young infants on mortality and the length of hospital stay (LOS). The isolates showed a high level of resistance against multiple antibiotic classes. Higher rates of antibiotic
Hospital-acquired infections and antibiotic resistance patterns and their implications for global health

The most frequent HAI were pneumonia and sepsis. Other HAI were meningitis, gastrointestinal, surgical site infection, and urinary tract infection. These findings were similar to previous research in the same [18] or different settings [25,26,50].

Eighty-five percent of all isolates causing HAI were GNB. The bacteria mainly isolated were Acinetobacter baumanii (28%), Klebsiella pneumoniae (25%) and Pseudomonas aeruginosa (21%), followed by Escherichia coli (9%) and Serratia marcescens (3%). Most studies investigating sepsis [23,24,51–53], pneumonia [54] or HAI in general [11,12,18,25,26] found GNB as the main causative pathogens for neonatal HAI, fewer name gram-positive bacteria as the main agent [45,55,56]. The exact bacteriological profile of HAI depends on the setting and the type

Table 4. Logistic regression model with all-cause mortality as outcome.

| Variable                        | Odds ratio (OR) | 95% Confidence interval | p-value |
|---------------------------------|-----------------|--------------------------|---------|
| Exposure:                       |                 |                          |         |
| Multiple antibiotic resistance (MAR) score | 1.269         | 1.067–1.508              | 0.007   |
| Co-variates:                    |                 |                          |         |
| Time at risk                    | 1.000           | 1.000                    | 0.579   |
| Number of co-morbidities        | 0.952           | 0.678–1.336              | 0.775   |
| Number of medical devices       | 1.492           | 1.188–1.874              | 0.001   |
| Birthweight                     | 1.000           | 1.000                    | 0.618   |
| Sex*                            | 0.874           | 0.494–1.546              | 0.643   |
| Age at admission                | 1.007           | 0.979–1.036              | 0.632   |

*Sex coded as 0 = male, 1 = female; time at risk as baseline; OR > 1: risk factor, OR < 1 protective factor

Adjusting for different confounders, here listed as co-variates, multiple antibiotic resistance (MAR) was a significant risk factor for mortality, increasing the odds by 27%.

https://doi.org/10.1371/journal.pone.0215666.t004

resistance were significantly associated with higher mortality and a longer hospital stay when confounding factors were held constant.

The effect of multiple antibiotic resistance on neonatal mortality and morbidity

Table 5. Multiple linear regression model for 'length of hospital stay' (LOS) in days as outcome.

| Variable                        | B     | 95% Confidence interval of B | Standard error | p-value |
|---------------------------------|-------|-----------------------------|----------------|---------|
| Exposure:                       |       |                             |                |         |
| Multiple antibiotic resistance (MAR) score | 2.066 | 0.209–3.923                  | 0.947          | 0.029   |
| Co-variates:                    |       |                             |                |         |
| Time at risk in days            | -1.971E-5 | 0.000–0.000                  | 0.000          | 0.913   |
| Number of co-morbidities        | 3.078 | -0.791–6.948                 | 1.973          | 0.119   |
| Number of invasive devices      | 0.528 | -2.043–3.948                 | 1.311          | 0.687   |
| Sex*                            | -1.654 | -7.791–4.483                 | 3.131          | 0.597   |
| Age at admission in days        | -0.285 | -0.611–0.42                  | 0.166          | 0.087   |
| Birthweight in gram             | -0.010 | -0.14–0.007                  | 0.002          | < 0.001 |
| Crude mortality                 | -6.064 | -12.184–0.056                | 3.122          | 0.052   |

*Sex coded as 0 = male, 1 = female; B = unstandardized regression coefficient; 95% CI B = 95% confidence interval of B

Adjusting for important confounders, here listed as co-variates, the length of stay (LOS) in the hospital increased by 2.1 days with every increase in MAR score.

https://doi.org/10.1371/journal.pone.0215666.t005
of HAI investigated. Nevertheless, *Acinetobacter baumanii, Klebsiella pneumoniae, Pseudomonas aeruginosa*, and *Escherichia coli* were predominantly isolated in prior research, similarly to our study [18,24–26,51–54].

During the last decade, research increasingly focuses on multidrug resistance (MDR), extensive drug resistance (XDR) and pan-drug resistance (PDR) [15,57]. However, the use of these terms varies widely between studies, especially before Magiorakos et al. [15] offered a comprehensive definition of those classifications for common strains (Magiorakos et al. [15]: ‘MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial categories.’). Previous studies investigating neonatal HAI found MDR in 11% [58], 35%-55% [24,25,32] and in 80% of all isolates [33,59]. The global reports on infections due to XDR and even PDR GNB are increasing and a cause for concern [60–62]. Teerawattanapong et al. [57] detected a particularly high burden of *Acinetobacter spp* with MDR, XDR or PDR in Southeast Asia compared to other regions. The exact definition suggested by Magiorakos et al. [15] could not be applied to the study at hand since bacteria were not tested for all required antibiotic classes, e.g. tetracyclines since they are contraindicated in neonates. Nevertheless, 70% to over 90% of isolates were resistant to antipseudomonal penicillins, cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and trimethoprim/sulfamethoxazole, suggesting a high rate of MDR and a considerable rate of XDR. However, these figures do not represent the prevalence of ABR in the area, which is presumably lower. Since the study was conducted in a tertiary hospital with many patients referred to due to infections, the numbers are overestimating the true prevalence of ABR. Le et al. [18] showed in an ICU point prevalence survey of HAI in five Vietnamese pediatric hospitals including a total of 1363 cases a carbapenem resistance between 55% in *Klebsiella pneumoniae* to 71% in *Acinetobacter baumanii* and a prevalence of cephalosporine resistance of 90% in *Klebsiella pneumoniae*.

The case fatality rate was 44.3% and similar to previous research indicating an overall neonatal fatality of 38 to 47% [19,53,63]. Of those that died, 71.7% died within 30 days after infection while Saleem et al. [19] report a similar proportion (70%) after only four days.

Comparing mortality as a consequence of ABR across the literature is challenging because of vast methodological differences. Risk factor and outcome studies are frequently combined, although not recommended [64] and study designs differ greatly. Unfortunately, not all investigators conduct multivariable analysis to adjust for confounders or effect modifiers. Although some papers [27,38–40] emphasize the need to control for co-morbidities, the severity of illness and the time spent in a health facility before infection (time at risk), this is not yet common practice, possibly leading to biased results. The co-variates included vary across the field, sometimes exceeding the capacity of the sample size, decreasing the power.

**Antibiotic resistance as a risk factor for mortality**

In our study, multiple antibiotic resistance (MAR) in GNB remained a significant risk factor for mortality in neonates with HAI after adjusting for potential confounders. This association might be attributable to changes in the bacteria to withstand the host’s immune defense, however, several studies report a reduced fitness in resistant strains compared to susceptible strains [65–67]. Consistent with prior research, we assume that delayed appropriate treatment and the absence of effective drugs in cases resistant to all tested substances contribute to the increased mortality in our cohort since empiric treatment might fail due to ABR [36,68–71]. Data about the exact dates and dosage of antibiotic therapy were not available to us, hence we lack strong
evidence to support our hypothesis. However, the authors observed that although local recommendations for antibiotic treatment consider the prevalence of ABR in this setting, first line antibiotics were often ineffective in patients with HAI caused by MDR pathogens. Consequently, appropriate treatment is delayed by the time clinicians receive microbiological test results including sensibility testing. In those cases where all antibiotics were tested resistant (6.4%) and empirical therapy was therefore certainly inadequate, mortality was highest. In these patients, a combination of different substances was administered, hoping for a residual antibiotic effect in vivo.

So far, not many studies investigated mortality due to ABR in neonates. Focus often lies upon a single type of infection, bacteria or antibiotic class, studies including multiple antibiotic classes are rare.

In general, our study confirms previous findings. While only a few studies did not identify ABR as a risk factor for mortality in neonates [72], the majority have found significant associations. For instance, mortality was reported to be higher in patients infected by ESBL-producing GNB [29,31] or by GNB with carbapenem resistance [30], increasing the odds of dying 3- to 4-fold.

Most research focusing on resistance to multiple antibiotic classes indicates an association with mortality. Al Jarousha et al. [32] found a mortality rate of 37.5% in NICU patients infected with MDR Acinetobacter spp. compared to only 12% in controls. However, controls were uninfected, so the result might be more attributable to the infection itself than to ABR. Folgori et al. [25] found a 30 days mortality rate of 19% in patients with HAI caused by MDR strains compared to 13% in susceptible strains (p = 0.06) in neonates and children. Others [24] reported similar results with a fatality rate of 16% in patients with sepsis caused by MDR bacteria compared to 12% in those with susceptible strains and 8% in controls with culture negative sepsis.

However, only a few studies adjust for confounders, which is essential if ABR is claimed to be a risk factor for mortality. In two elaborate studies which included two control groups each and adjusted for confounders, Thatrimontrichai et al. [33,34] reported carbapenem resistance to be a significant risk factor for mortality in patients with infections caused by Acinetobacter spp. The mortality was significantly higher in bloodstream infections caused by resistant strains compared to those caused by susceptible strains (OR = 5). These results are similar to ours, as we identified MAR as a risk factor for mortality with an OR of 1.3, however assessing a broader spectrum of bacteria, infections, and antibiotic classes.

**Prolonged length of hospital stay attributable to antibiotic resistance**

Studies assessing LOS in neonates are scarce and varying with respect to the type of infection, pathogen, and antibiotic resistance pattern. Abdel-Hady et al. [31] and Sehgal et al. [29] found that the hospital stay was prolonged in patients infected with ESBL-producing GNB. In a study conducted by Thatrimontrichai et al. [34], hospital stay was longer in patients with pneumonia caused by carbapenem-resistant Acinetobacter spp., however, the result was not significant. In children admitted to an ICU, infections with a resistant strain seem to prolong the hospital stay compared to infections caused by a susceptible strain in some studies [73], others found no significant difference [74].

Focusing on MDR, despite the varying definition of this variable, Mauldin et al. [75] assessed the LOS in patients from all age groups admitted to the general ward or ICU with HAI. They and concluded that LOS was prolonged by 24% in patients infected with MDR strains. Other studies including adults [9,71,76] also indicate a longer hospital stay if an infection is caused by resistant compared to susceptible bacteria.
However, the vast majority of those studies did not control for confounders, especially for the 'time at risk'. Exposure to healthcare is a risk factor to acquire colonization or infection with ABR bacteria due to cross-transmission or selective pressure on the microbiome during antibiotic treatment [7,34,40]. Reversely, an infection with a resistant strain can prolong the hospital stay since it might be more difficult to treat [7,31,77]. Thus, ABR can present the cause or the consequence of a prolonged hospital stay. To ensure that only LOS attributable to ABR is assessed, 'time at risk', the time before infection occurs, should be entered as a confounder in the multivariate analysis [27,41]. One of the few studies controlling for 'time at risk' and co-morbidities found increased mortality (OR 4.4) and a longer hospital stay (hazard ratio 2) in patients with MDR *Pseudomonas spp.* infection compared to susceptible controls [78]. Lower birthweight was significantly associated with increased LOS and should therefore always be included as a confounder. Mortality was an almost significant co-variate in our regression model, demonstrating the importance to control for this confounder when assessing LOS. Our study, likewise adjusting for possible confounders, found an increase of LOS by 2.1 days for every additional resistance to an antibiotic class.

**Strengths**

A strength of this study is the considerable sample size and adjustment for important confounders such as co-morbidities and 'time at risk' as well as for possible effect modifiers. Most studies identified birthweight or gestational age as a significant effect modifier when generally assessing mortality in neonates. Especially preterm neonates are at a higher risk for adverse outcomes with a compromised immune system and other underlying diseases [19,53]. For future studies investigating ABR-related mortality in neonates, we hence suggest including birthweight, gestational age, age at admission and sex as possible effect modifiers in the multivariate analysis.

**Limitations**

Obtaining tracheal aspirate and nasopharyngeal cultures always entails a potential risk of contamination with bacterial species other than the one or those causing pneumonia. The gold standard in adults however, the bronchoalveolar lavage, can be harmful in severely ill neonates. Since the bacterial species included in this study (*Klebsiella pneumonia, Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli* and/or *Serratia marcescens*) are not part of the typical nasopharyngeal flora, the attending physicians in the vast majority of cases treated the patients based on the assumption that the pathogens isolated using tracheal aspirates and nasopharyngeal cultures are de facto causing the HAI. Furthermore, many neonates with pneumonia developed a secondary sepsis that allowed us to confirm the causative pathogen in blood cultures.

Since we lacked the exact dates and dosages of drug administration, we cannot ultimately prove if inappropriate empirical treatment is the underlying reason for the adverse outcomes observed.

To adjust for 'severity of illness', the number of invasive devices was used as a surrogate parameter as well as other important factors recommended in existing scoring systems. This approach is likely to minimize the influence of 'severity of illness' on the outcome, however, it is no validated method and we cannot exclude residual confounding. As already discussed earlier, a more favorable approach to control for this confounder would be a validated score including clinical and feasible laboratory parameters. This score should preferably be assessed before and with the onset of an HAI to adjust for the severity of the underlying disease as well as for the severity of the HAI itself (the mortality in sepsis is presumably higher than that of a
simple urinary tract infection, irrespective of ABR). Another possibility might be to adjust for the type of HAI, however, this would have reduced our sample size and with it the statistical power.

Our variable ‘time at risk’ which adjusts for previous exposure to healthcare only accounts for the time since admission to the hospital, the time of prior hospital stays in case of referral was not considered.

Because of missing information, we were unable to compare MDR and non-MDR bacteria according to the definition by Magiorakos et al. [15] and introduced the variable MAR instead. Nevertheless, we first tried the analysis with a binary variable similar to this definition. Yet no significant results were obtained. We conclude that dichotomizing a continuous variable, such as the number of resistances to different antibiotic classes, leads to loss of information and can reduce the discriminatory power. This might be a reason why several studies were unable to detect a difference between infections caused by MDR and non-MDR bacteria. Using a continuous variable as we did might, therefore, present an alternative approach.

**Conclusion**

Antibiotic resistance in gram-negative bacteria, here measured as resistance to multiple antibiotic classes, is a significant risk factor for mortality and prolonged hospital stay in patients admitted to a neonatal intensive care unit with hospital-acquired infections in the Vietnamese context. The adjustment for confounders such as co-morbidities, severity of illness and time at risk is essential to prevent biased results, yet not common practice in the field.

In line with previous research, this study emphasizes that antibiotic resistance is an increasing burden for global health, especially for vulnerable patients such as neonatal intensive care patients in resource-constraint settings. Tackling antibiotic resistance must become a priority for the global community to reduce mortality, morbidity and healthcare expenses.

**Supporting information**

S1 Table. Proportion of missing data in the variables of interest. The table shows the percentage of missing data in each of the variables of interest across the complete dataset (n = 327).

(S1 Data. The primary data our statistical analysis is based on.)

**Acknowledgments**

We would like to thank: The Swedish Foundation for International Cooperation in Research and Higher Education (STINT) for the support, Training and Research Academic Collaboration (TRAC) to have student knowledge exchange and capacity building between Sweden and Vietnam. The Swedish research council (VR) and EU Marie Curie for support, the staff of Vietnam National Children’s Hospital (VNCH) to let us do important research with data collected and to our different universities for giving us time to do research. The first author wants to thank the Else Kröner-Fresenius-Stiftung for a scholarship that allowed a master’s degree and hence working on this project.
Author Contributions

Conceptionalization: Linus Olson, Dung T. K. Khu, Ngoc T. B. Hoang, Dien M. Tran, Mattias Larsson.

Data curation: Lynn Peters, Linus Olson, Ngai K. Le, Ngoc T. B. Hoang, Mattias Larsson.

Formal analysis: Lynn Peters.

Funding acquisition: Linus Olson.

Investigation: Linus Olson, Ngai K. Le, Ngoc T. B. Hoang, Dien M. Tran, Mattias Larsson.

Methodology: Lynn Peters, Linus Olson, Sofia Linnros, Dien M. Tran, Mattias Larsson.

Project administration: Linus Olson, Dung T. K. Khu, Ngai K. Le, Mattias Larsson.

Resources: Linus Olson, Ngoc T. B. Hoang.

Supervision: Linus Olson, Ngai K. Le, Ngoc T. B. Hoang, Dien M. Tran, Mattias Larsson.

Validation: Linus Olson, Mattias Larsson.

Visualization: Lynn Peters.

Writing – original draft: Lynn Peters.

Writing – review & editing: Linus Olson, Dung T. K. Khu, Sofia Linnros, Ngai K. Le, Håkan Hanberger, Ngoc T. B. Hoang, Dien M. Tran, Mattias Larsson.

References

1. CDC About Antimicrobial Resistance Atlanta: Centers for Disease Control and Prevention.
2. CDC (2013) Antibiotic resistance threats in the United States. In: Prevention CDCa, editor. Atlanta.
3. Chereau F, Opatowski L, Toudjman M, Vong S (2017) Risk assessment for antibiotic resistance in South East Asia. Bmj 358: j3393. https://doi.org/10.1136/bmjj3393 PMID: 28874338
4. Paphitou NI (2013) Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents 42 Suppl: S25–28.
5. Koffel MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134: 298–314. PMID: 11182841
6. Juan C, Gutierrez O, Oliver A, Ayestarane JI, Borrell N, Perez JL (2005) Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin Microbiol Infect 11: 887–892. https://doi.org/10.1111/j.1469-0691.2005.01251.x PMID: 16216103
7. Falagas ME, Kopterides P (2006) Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64: 7–15. https://doi.org/10.1016/j.jhin.2006.04.015 PMID: 16822583
8. Plano LR (2010) The changing spectrum of neonatal infectious disease. J Perinatol 30 Suppl: S16–20.
9. Lin MF, Lan CY (2014) Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2: 787–814. https://doi.org/10.12998/wjcc.v2.11.787 PMID: 25516653
10. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. (2011) Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 39: S1–34. https://doi.org/10.1016/j.ajic.2011.01.003 PMID: 21511081
11. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA (2005) Hospital-acquired neonatal infections in developing countries. Lancet 365: 1175–1188. https://doi.org/10.1016/S0140-6736(05)71881-X PMID: 15794973
12. Allegranzi B, Bagheri Nejad S, Combesecure C, Graafmans W, Attar H, Donaldson L, et al. (2011) Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 377: 228–241. https://doi.org/10.1016/S0140-6736(10)61458-4 PMID: 21146207
13. Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxta A, Simonsen GS, et al. (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU
and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19: 56–66. https://doi.org/10.1016/S1473-3099(18)30605-4 PMID: 30409683

14. Song JH (2015) ‘Antimicrobial resistance control in Asia’ from ‘AMR Control 2015—Overcoming Global Antimicrobial Resistance’. In: Dynamics WAAARaGH, editor. United Kingdom.

15. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID: 21793988

16. O’Neill J (2014) Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance.

17. WHO (2015) Worldwide Country Situation Analysis: Response to Antimicrobial Resistance. In: Organisation WH, editor. Geneva.

18. Le NK, Hf W, Vu PD, Khu DT, Le HT, Hoang BT, et al. (2016) High prevalence of hospital-acquired infections caused by gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: A multi-centre point prevalence survey. Medicine (Baltimore) 95: e4099.

19. Saleem AF, Ahmed I, Mir F, Ali SR, Zaidi AK (2009) Pan-resistant Acinetobacter infection in neonates in Karachi, Pakistan. J Infect Dev Ctries 4: 30–37. PMID: 20130376

20. (2017) Levels and Trends in Child Mortality—Report 2017. New York, USA. 40 p.

21. UNICEF (2018) Every Child Alive—The urgent need to end newborn deaths. Geneva, Switzerland: United Nations Children's Fund.

22. Kaye KS, Pogue JM (2015) Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management. Pharmacotherapy 35: 949–962. https://doi.org/10.1002/phar.1636 PMID: 26497481

23. Bas AY, Demirel N, Zenciroglu A, Gol N, Tanir G (2010) Nosocomial blood stream infections in a neonatal intensive care unit in Ankara, Turkey. Turk J Pediatr 52: 464–470. PMID: 21434530

24. (2016) Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health 4: e752–760. https://doi.org/10.1016/S2214-109X(16)30148-6 PMID: 27633433

25. Folgori L, Bernaschi P, Piga S, Carletti M, Cunha FP, Lara PH, et al. (2016) Healthcare-Associated Infections in Pediatric and Neonatal Intensive Care Units: Impact of Underlying Risk Factors and Antimicrobial Resistance on 30-Day Case-Fatality in Italy and Brazil. Infect Control Hosp Epidemiol 37: 1302–1309. https://doi.org/10.1017/ice.2016.185 PMID: 27511591

26. Xu XF, Ma XL, Chen Z, Shi LP, Du LZ (2010) Clinical characteristics of nosocomial infections in neonatal intensive care unit in eastern China. J Perinat Med 38: 431–437. https://doi.org/10.1515/JPM.2010.063 PMID: 20297900

27. Cosgrove SE, Carmeli Y (2003) The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 36: 1433–1437. https://doi.org/10.1086/375081 PMID: 12766839

28. Cosgrove SE, Kaye KS, Eliopoulos GM, Carmeli Y (2002) Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 162: 185–190. PMID: 11802752

29. Sehgal R, Gaidn R, Chellani H, Agarwal P (2007) Extended-spectrum beta lactamase-producing gram-negative bacteria: clinical profile and outcome in a neonatal intensive care unit. Ann Trop Paediatr 27: 45–54. https://doi.org/10.1179/146532807X170501 PMID: 17469732

30. Punpanich W, Nithitamsakun N, Treeratweroaphong V, Suntarattiwong P (2010) Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children. Int J Infect Dis 16: e811–815. https://doi.org/10.1016/j.ijid.2012.07.006 PMID: 22898148

31. Abdel-Hady H, Hawas S, El-Daker M, El-Kady R (2008) Extended-spectrum beta-lactamase producing Klebsiella pneumoniae in neonatal intensive care unit. J Perinatol 28: 685–690. https://doi.org/10.1038/jp.2008.73 PMID: 18580881

32. Al Jarousha AM, El Jadba AH, Al Afifi AS, El Quouqa IA (2009) Nosocomial multidrug-resistant Acinetobacter baumannii in the neonatal intensive care unit in Gaza City, Palestine. Int J Infect Dis 13: 623–628. https://doi.org/10.1016/j.ijid.2008.08.029 PMID: 19144555

33. Thaatrimontchai A, Apisarnthanarak A, Chanvitan P, Janjindamai W, Dissaneevate S, Maneenil G (2013) Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case-case-control study. Pediatr Infect Dis J 32: 140–145. https://doi.org/10.1097 INF.0b013e318270b108 PMID: 22935672

34. Thaatrimontchai A, Techato C, Dissaneevate S, Janjindamai W, Maneenil G, Kritsaneepaiboos S, et al. (2016) Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study. J Infect Chemother 22: 444–449. https://doi.org/10.1016/j.jiac.2016.03.013 PMID: 27229539
35. Wei HM, Hsu YL, Lin HC, Hsieh TH, Yen TY, Lin HC, et al. (2015) Multidrug-resistant Acinetobacter baumannii infection among neonates in a neonatal intensive care unit at a medical center in central Taiwan. J Microbiol Immunol Infect 48: 531–539. https://doi.org/10.1016/j.jmii.2014.08.025 PMID: 25442873

36. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen MA, Fraser VJ (2004) Antimicrobial use and the influence of inadequate empiric antimicrobial therapy on the outcomes of nosocomial bloodstream infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol 25: 735–741. https://doi.org/10.1086/502469 PMID: 15487979

37. ECDC (2016) Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Protocol version 5.3. In: Control ECfDPa, editor. Stockholm: ECDC. pp. 22–24.

38. Schwaber MJ, Carmeli Y (2009) The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. Crit Care 13: 106. https://doi.org/10.1186/cc7136 PMID: 19216721

39. Schwaber MJ, Carmeli Y (2006) Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care 10: 164. https://doi.org/10.1186/cc5019 PMID: 16982010

40. Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ (2013) Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev 26: 289–307. https://doi.org/10.1128/CMR.00001-13 PMID: 23554418

41. Maragakis LL, Perencevich EN, Cosgrove SE (2008) Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 6: 751–763. https://doi.org/10.1586/14787210.6.5.751 PMID: 18847410

42. Garg B, Sharma D, Farahbakhsh N (2018) Assessment of sickness severity of illness in neonates: review of various neonatal illness scoring systems. J Matern Fetal Neonatal Med 31: 1373–1380. https://doi.org/10.1080/14767058.2017.1315665 PMID: 28372507

43. Dorling JS, Field DJ, Manktelow B (2005) Neonatal disease severity scoring systems. Arch Dis Child Fetal Neonatal Ed 90: F11–16. https://doi.org/10.1136/adc.2003.048488 PMID: 15613564

44. Sonmez MC, Ertem G, Erdinc FS, Kaya Kilic E, Tulek N (2016) Evaluation of Risk Factors for Antibiotic Resistance in Patients with Nosocomial Infections Caused by Pseudomonas aeruginosa. 2016: 1321487.

45. Al-Taiair A, Hammoud MS, Cuqing L, Lee JK, Lui KM, Nakwan N, et al. (2013) Neonatal infections in China, Malaysia, Hong Kong and Thailand. Arch Dis Child Fetal Neonatal Ed 98: F249–255. https://doi.org/10.1136/archdischild-2012-301767 PMID: 22942104

46. Newgard CD, Haukoos JS (2007) Advanced statistics: missing data in clinical research—part 2: multiple imputation. Acad Emerg Med 14: 669–678. https://doi.org/10.1197/j.aem.2006.11.038

47. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49: 1373–1379. PMID: 8970487

48. R. Wilson Van Voorhis C, Morgan B (2007) Understanding Power and Rules of Thumb for Determining Sample Size.

49. Green SB (1991) How Many Subjects Does It Take To Do A Regression Analysis. Multivariate Behav Res 26: 499–510. https://doi.org/10.1207/s15327906mbr2603_7 PMID: 26776715

50. Zhang TO, Dong L, Wang ZY, Li HY (2011) [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children]. Zhonghua Er Ke Za Zhi 49: 545–549. PMID: 22088187

51. Nikkho B, Lahrpur F, Delpisheh A, Rassouli MA, Akhamzadeh A (2015) Neonatal blood stream infections in tertiary referral hospitals in Kurdistan, Iran. Ital J Pediatr 41: 43. https://doi.org/10.1186/s13052-015-0136-4 PMID: 26051617

52. Shitaye D, Asrat D, Woldeamanuel Y, Worku B (2010) Risk factors and etiology of neonatal sepsis in Tikur Anbessa University Hospital. Ethiopia. Ethiop Med J 48: 11–21. PMID: 20607993

53. Morkel G, Bekker A, Marais BJ, Kirsten G, van Wyk J, Dramowski A (2014) Bloodstream infections and antimicrobial resistance patterns in a South African neonatal intensive care unit. Paediatr Int Child Health 34: 108–114. https://doi.org/10.1179/2046905513Y.0000000082 PMID: 24621234

54. Tan B, Xian-Yang X, Zhang X, Peng-Zhou X, Wang P, Xue J, et al. (2014) Epidemiology of pathogens and drug resistance of ventilator-associated pneumonia in Chinese neonatal intensive care units: a meta-analysis. Am J Infect Control 42: 902–910. https://doi.org/10.1016/j.ajic.2014.05.007 PMID: 25087143

55. Tiskumara R, Fakharee SH, Liu CQ, Nuntkurumit P, Lui KM, Hammoud M, et al. (2009) Neonatal infections in Asia. Arch Dis Child Fetal Neonatal Ed 94: F144–148. https://doi.org/10.1136/adc.2008.139865 PMID: 18805822
63. (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388–416. https://doi.org/10.1164/rccm.200405-644ST PMID: 15699079

64. Johnson PJ (2012) Antibiotic resistance in the NICU. Neonatal Netw 31: 109–114. https://doi.org/10.1891/0730-0832.31.2.109 PMID: 22397796

65. Teerawattanapong N, Panich P, Kulpokin D, Na Ranong S, Kongpakwattana K, Saksinanon A, et al. (2018) A Systematic Review of the Burden of Multidrug-Resistant Healthcare-Associated Infections Among Intensive Care Unit Patients in Southeast Asia: The Rise of Multidrug-Resistant Acinetobacterbaumannii. Infect Control Hosp Epidemiol 39: 525–533. https://doi.org/10.1017/ice.2018.58 PMID: 29580299

66. Yang MA, Lee J, Choi EH, Lee HJ (2011) Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes. J Korean Med Sci 26: 612–618. https://doi.org/10.3346/jkms.2011.26.5.612 PMID: 21532850

59. Viswanathan R, Singh AK, Basu S, Chatterjee S, Sardar S, Isaacs D (2012) Multi-drug resistant gram negative bacilli causing early neonatal sepsis in India. Arch Dis Child Fetal Neonatal Ed 97: F182–187. https://doi.org/10.1136/archdischild-2011-300097 PMID: 22155619

60. Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, et al. (2011) Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatr Pulmonol 46: 60–66. https://doi.org/10.1002/ppul.21324 PMID: 20812247

61. Zwee-Han K, Milisana KP, Pillay M (2017) Analysis of clinical and microbiological data on Acinetobacter baumannii strains assist the preauthorization of antibiotics at the patient level for an effective antibiotic stewardship program. J Infect Public Health 10: 608–616. https://doi.org/10.1016/j.jiph.2017.01.014 PMID: 28237694

62. Salehi B, Goudarzi H, Nikmanesh B, Houri H, Alavi-Moghaddam M, Ghalavand Z (2018) Emergence and characterization of nosocomial multidrug-resistant and extensively drug-resistant Acinetobacter baumannii isolates in Tehran, Iran. J Infect Chemother.

63. (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388–416. https://doi.org/10.1164/rccm.200405-644ST PMID: 15699079

64. Evans SR, Harris AD (2017) Methods and issues in studies of CRE. Virulence 8: 453–459. https://doi.org/10.1080/21505594.2016.1213473 PMID: 27470534

65. Basra P, Alsaaadi A, Bernal-Astrain G, O’Sullivan ML, Hazlett B, Clarke LM, et al. (2018) Fitness trade-offs of antibiotic resistance in extra-intestinal pathogenic Escherichia coli. Genome biology and evolution 10: 667–679.

66. Björkman J, Andersson DI (2000) The cost of antibiotic resistance from a bacterial perspective. Drug Resistance Updates 3: 237–245. https://doi.org/10.1011/eva.20149385

67. Melnych AH, Wong A, Kassen R (2015) The fitness costs of antibiotic resistance mutations. Evolutionary applications 8: 273–283. https://doi.org/10.1111/eva.12196 PMID: 25861385

68. Ivady B, Kenesei E, Toth-Heyn P, Kertesz G, Tarkanyi K, Kassa C, et al. (2016) Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children. Infection 44: 309–321. https://doi.org/10.1007/s15010-015-0857-8 PMID: 26546372

69. Prata-Rocha ML, Gontijo-Filho PP, Melo GB (2012) Factors influencing survival in patients with multi-drug-resistant Acinetobacter baumannii infection. Braz J Infect Dis 16: 237–241. PMID: 22729190

70. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E (2005) Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med 165: 1375–1380. https://doi.org/10.1001/archinte.165.12.1375 PMID: 15983286

71. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM (2014) Pseudomonas aeruginosa bacteremia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol 63: 1679–1687. https://doi.org/10.1099/jmm.0.073262-0 PMID: 25261066

72. Kumar A, Randhawa VS, Nirupam N, Rai Y, Sall I (2014) Risk factors for carbapenem-resistant Acinetobacter baumannii bloodstream infections in a neonatal intensive care unit, Delhi, India. J Infect Dev Ctries 8: 1049–1054. https://doi.org/10.3955/jidc.4246 PMID: 25116673

73. Foglia EE, Fraser VJ, Elward AM (2007) Effect of nosocomial infections due to antibiotic-resistant organisms on length of stay and mortality in the pediatric intensive care unit. Infect Control Hosp Epidemiol 28: 299–306. https://doi.org/10.1086/512628 PMID: 17320020

74. Zaoutis TE, Goyal M, Chiu JH, Coffin SE, Bell LM, Nachamkin I, et al. (2005) Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 115: 942–949. https://doi.org/10.1542/peds.2004-1289 PMID: 15805368
75. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA (2010) Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 54: 109–115. https://doi.org/10.1128/AAC.01041-09 PMID: 19841152

76. Ozgur ES, Horasan ES, Karaca K, Ersoz G, Nayci Atis S, Kaya A (2014) Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control 42: 206–208. https://doi.org/10.1016/j.ajic.2013.09.003 PMID: 24485378

77. Leblebicioglu H, Ozturk R, Rosenthal VD, Akan OA, Sirmatel F, Ozdemir D, et al. (2013) Impact of a multidimensional infection control approach on central line-associated bloodstream infections rates in adult intensive care units of 8 cities of Turkey: findings of the International Nosocomial Infection Control Consortium (INICC). Ann Clin Microbiol Antimicrob 12: 10. https://doi.org/10.1186/1476-0711-12-10 PMID: 23641950

78. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50: 43–48. https://doi.org/10.1128/AAC.50.1.43-48.2006 PMID: 16377685